EMA gives thumbs up to Almirall’s atopic dermatitis medicine Lebrikizumab

Almirall edificio id

Bankinter: Ebglyss (lebrikizumab) receives positive opinion from the European Medical Agency’s advisory committee. The Target Price is raised from €9.50/share to €10/share .

The positive opinion of the committee has to be reviewed by the European Commission, which issues the marketing authorisation. This step could take 2-3 months and, if ratified, the commercial launch of Ebglyss will be almost immediate. The drug is a treatment for moderate to severe atopic dermatitis that has been developed by Eli Lilly, Almirall (ALM) has exclusive rights to market it in Europe.

Assessment: Positive news, although expected after the positive results of the latest clinical trials with Ebglyss, which will compete against Dupixent (Sanofi), from which we expect a competitive commercial policy to defend the positioning of its leading drug in sales. We raise our Target Price for Almirall to 10.00 eur/share (9.50 eur/sh. prev.). We reiterate our Neutral recommendation.

About the Author

The Corner
The Corner has a team of on-the-ground reporters in capital cities ranging from New York to Beijing. Their stories are edited by the teams at the Spanish magazine Consejeros (for members of companies’ boards of directors) and at the stock market news site Consenso Del Mercado (market consensus). They have worked in economics and communication for over 25 years.